- Salvigenin
-
- $65.00
-
2026-07-15
- CAS:19103-54-9
- Purity: 99.78%
- Supply Ability: 10g
- Salvigenin
-
-
2023-02-24
- CAS:19103-54-9
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- salvigenin
-
- $8.00
-
2020-02-21
- CAS:19103-54-9
- Min. Order: 1g
- Purity: ＞98% HPLC
|
| | salvigenin Basic information |
| Product Name: | salvigenin | | Synonyms: | 5-Hydroxy-6,7-dimethoxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one;4H-1-Benzopyran-4-one, 5-hydroxy-6,7-dimethoxy-2-(4-methoxyphenyl)-;5-hydroxy-6,7-dimethoxy-2-(4-methoxyphenyl)chromen-4-one;Salvigenin,inhibit,Apoptosis,immunomodulatory,ROS Kinase,Autophagy,Inhibitor,neuroprotective,antioxidant;Salvigenin
Salvigenin;Salvigenin, 10 mM in DMSO | | CAS: | 19103-54-9 | | MF: | C18H16O6 | | MW: | 328.32 | | EINECS: | | | Product Categories: | Tetra-substituted Flavones | | Mol File: | 19103-54-9.mol |  |
| | salvigenin Chemical Properties |
| Melting point | 188 °C | | Boiling point | 535.9±50.0 °C(Predicted) | | density | 1.314±0.06 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | form | powder | | pka | 6.33±0.40(Predicted) | | color | Yellow |
| | salvigenin Usage And Synthesis |
| Uses | Salvigenin is a neuroprotective agent used in the treatment of neurodegenerative diseases acting through oxidative stress on cells. | | Definition | ChEBI: Salvigenin is a trimethoxyflavone that is scutellarein in which the hydroxy groups at positions 4', 6, and 7 are replaced by methoxy groups. It has a role as an autophagy inducer, an apoptosis inhibitor, an antilipemic drug, an immunomodulator, an antineoplastic agent, a neuroprotective agent, a hypoglycemic agent and a plant metabolite. It is a trimethoxyflavone and a monohydroxyflavone. It is functionally related to a scutellarein. | | in vivo | Salvigenin (0-9.68 μg/mouse/day; i.p.; 4 or 12 days) shows antitumor and immunomodulatory effects on tumor bearing mice[2]. | Animal Model: | MCF-7 cell bearing inbred female Balb/c mice, aged from six to eight weeks[2] | | Dosage: | 3.65, 5.85 and 9.68 μg/mouse/day for four days or 12 days | | Administration: | Intraperitoneal injection | | Result: | Showed a significant increase in DTH response in a dose-dependent manner. Significantly decreased the rate of tumor growth, increased lymphocyte proliferation index, increased the level of IFN-γ and decreased IL-4 production. Exhibited a significant decrease of the splenic CD4+CD25+Foxp3+ T lymphocytes. |
|
| | salvigenin Preparation Products And Raw materials |
|